Zenosense has been working with a
large university hospital in Madrid, Spain to test the effectiveness of its
specially designed volatile organic compound (VOC) detection techniques. The
collaboration is particularly promising, because, in addition to its work with
Zenosense, the university hospital has been directly involved in a number of
published studies focusing on the detection of VOCs in order to better identify
various respiratory pathologies.
While the 400 subject trial will
serve as an excellent proof of concept, Zenosense hopes to considerably
increase the size of its tests following positive initial results. The company
expects the initial trial to take nine months and involve four distinct groups
of subjects including healthy smokers, non-smokers and those with diagnosed
lung cancer and Chronic Obstructive Pulmonary Disease. The company has already
been approved by the ethics committee of the university hospital, meaning that
broadening participation to include a host of other public hospitals throughout
Spain is possible without the need for further approvals.
If the trials prove successful,
Zenosense will be one step closer to taking its revolutionary diagnostic
systems to the market. By allowing for superior early detection of lung cancer
through non-invasive means, there’s little doubt that the company’s devices
would be in a great position to experience tremendous demand. The company
predicts that having a way to improve early detection through cost effective
screening techniques could offer noticeable improvements to the survivability
rates of lung cancer and similar ailments.
VOC detection is a tried and tested
method of diagnosing diseases. Just as highly trained dogs have been able to
recognize prostate cancer-specific VOCs with up to 98 percent accuracy,
Zenosense’s use of a common Electronic Nose technology platform puts it in a
great position to improve diagnostic accuracy for a wide range of diseases.
As the company’s trial continues to
ramp up, look for Zenosense to make some major waves in the medical and
diagnostic industries in the near future. With the possibility of dramatically
improving the survivability of some of the world’s most deadly illnesses and
servicing multi-billion dollar industries, the sky could be the limit for this
detection device development company.
For more information on the company,
visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment